Second Generation Fatty Acid Compositions, Formulations, and Methods of Use and Synthesis Thereof

Abstract

An orally administered fatty acid composition for the treatment of cardiovascular diseases, and a method of treating same, are provided. The compound includes 5Z,8Z,11Z,14Z,17Z-eicosapentaenoic ethanolamide (EPA ethanolamide), 4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoic ethanolamide (DHA ethanolamide), and at least one tocotrienol. The EPA ethanolamide and the DHA ethanolamide are preferably each substantially in a range of 100-900 mg per dosage form. The at least one tocotrienol is substantially in a range of 10-500 mg per dosage form. The at least one tocotrienol includes at least one of α-tocotrienol, β-tocotrienol, γ-tocotrienol, or δ-tocotrienol and is preferably substantially tocopherol-free. The composition may take the form of a medical food or a pharmaceutical preparation. A preferred formulation of the composition includes approximately 525 mg EPA ethanolamide, approximately 315 mg DHA ethanolamide, and approximately 50 mg δ-tocotrienol. The EPA and DHA ethanolamides may be synthesized from fatty acid triglycerides.

1 - 31 . (canceled) 
     
     
         32 . An orally administered fatty acid composition, comprising:
 ethanolamine 5Z,8Z,11Z,14Z,17Z-eicosapentaenoate salt (ethanolamine EPA);   ethanolamine 4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoate (ethanolamine DHA); and   at least one tocotrienol, wherein said composition has a total aerobic plate count per g/mL of less than 20,000 cfu.